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The diagnostic value of methylated DNA in laryngeal squamous  
cell carcinoma: meta-analysis
ZHJ Li1†, W Gao1†, WB Lei2, WK Ho1, YWJ Chan1, TS Wong1*
Abstract
BackgroundLaryngeal squamous cell carcinoma (LSCC) is the second most common 
head and neck squamous cell carci-
noma (HNSCC). Although early detec-tion of LSCC is a good prognostic factor for patients, they usually present late and with high recurrence rate. The use of methylated deoxyribonucleic acid (DNA) is considered to be a good 
surrogate marker of cancer as each cancer type has a specific methylation phenotype, which is distinguishable from the normal counterparts. Although intensive efforts had been made on 
the clinical use of methylation markers for cancer surveillance, the use of methylated DNA in differentiating LSCC patients remains unclear.
MethodsPooled sensitivity and specificity, 
positive likelihood ratio (PLR), nega-
tive likelihood ratio (NLR) and the summary estimates of diagnostic odds 
ratio (DOR) were elucidated from the synthesized data. The diagnostic per-
formance of methylated DNA markers was assessed by summary receiver 
operating curve (SROC) using random-effects models. Publication bias was 
examined with the use of Deeks’ funnel plot.
Results
Data from 27 studies containing 2262 tissue samples were extracted. Among 
the 16 methylated DNA markers, which 
had been applied on LSCC, 6 of the 
16 (37.5%) methylated genes were statistically significant (P < 0.05) in differentiating cancerous tissues from the normal counterparts. Combined 
sensitivity and specificity were 0.62 
(95% CI: 0.46–0.76) and 0.91 
(95% CI: 0.79–0.97), respectively; 
the pooled PLR and NLR were 7.2 
(95% CI: 2.5–20.4) and 0.42 (95% CI: 
0.27–0.65), respectively, and DOR 
was 17 (95% CI: 4–69).
ConclusionBecause aberrant DNA methylation occurs in the early developmental 
stages of LSCC, methylation markers are good for the detection of visually undetectable cases in LSCC tissues. 
However, based on the current mark-ers panel, the accuracy of methylated 
DNA markers is not satisfactory for 
clinical use. Identification of novel 
methylated markers with higher sensi-tivity and specificity is warranted.
IntroductionThe larynx is the second most com-
mon site for head and neck cancer development1. The larynx could be divided into 3 parts including the glottis, supraglottis, and subglottis, and laryngeal carcinoma usually originates in the glottis and supraglottis2. 
Histologically, most of the laryngeal carcinoma is squamous cell carcinoma (LSCC). Despite the advances in molec-ular diagnostic and therapeutic modalities in the previous decades, the diagnosis and prognosis of LSCC patients showed no significant 
improvement. The 5-year survival of patients with LSCC remains unchanged. 
In the United States, the mortality rate caused by LSCC changed from 2.97 
(year 1990) to 2.05 (year 2007) with 
no significant improvement3. Early diagnosis improves the prognosis of patients with carcinoma in this region. Symptoms for LSCC include voice change, hoarseness, swallowing 
difficulties and dyspnoea. In general, patients perceive the symptoms as innocuous conditions, leading to a delay in diagnosis4. Some symptoms such as voice change may occur only in the later stage of disease (e.g. supra-glottic carcinoma), resulting in a delay in treatment. Early detection is impor-tant because it is the determining factor for curative and function-preserving therapy5. However, at present, there is 
still no molecular marker for use in early diagnosis of the disease.Deoxyribonucleic acid (DNA) meth-ylation refers to the covalent addition of a methyl group by DNA methyl-transferases to the cytosine residue of 
the CpG islands (around 500 bp to 2000 bp) in gene regulatory regions6. 
In normal cells, tumour suppressor genes are usually unmethylated7. The additional methyl group will alter the chromatin structure, which changes the transcriptional rate of the asso-ciated genes. Further, the methylated cytosine residue has a higher muta-
tion rate and is linked with the allelic loss observed in human malignan-cies. Methylated tumour suppressor genes are frequently reported in cancerous tissues and are used to differentiate clinical samples con-taining preneoplastic and/or tumour cells from the normal counterparts8. The methylated DNA is suitable for use 
as an early cancer biomarker because DNA methylation is an early event in the carcinogenic process and is regarded as an early indicator for cancer development before symp-toms arise9. At present, methylated 
* Corresponding author
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DNA is under clinical assay and is mov-ing on to retrospective or longitudinal studies7,10.
The use of molecular markers in cancer diagnosis has emerged as an 
effective approach because these mark-ers are sensitive and have a high pre-
dictive value. In LSCC, however, there is still no consensus on the impact of 
molecular markers as early screening tools. Although the diagnostic value of methylated DNA has been extensively studied in other solid tumours and is suggested to be clinically useful in specific cases, its clinical significance in LSCC diagnosis remains unresolved. Therefore, we report an evaluation of the diagnostic accuracy of methylated 
DNA as biomarkers for LSCC diagnosis.
Methods and materials
Search strategyA systematic literature search (publi-
cations from 1980 to January 2013) was performed independently by two 
authors (LZH and GW) in PubMed, 
EMBASE, Medline and Springer link, using ‘laryngeal/ larynx/glottis/supra-
glottic/subglottic’, ‘cancer/carcinoma’ 
and ‘methylation/hypermethylation/ 
hypomethylation/demethylation’ as 
keywords. No restriction was set dur-ing this search. Duplicated results, irrel-evant articles and publications not in English or Chinese were removed from this study. Papers of non-case-control studies were further excluded. Lastly, 
articles lacking in gene methylation fre-quency data or without exclusive meth-ylation frequency and papers involving 
microRNA methylation in LSCC were also excluded.
Data extraction and quality 
assessment
Information extracted from the selected papers included first author, publication year, study area, research genes, case populations, test methods and the true-positive (TP), false-positive (FP), false-negative (FN) and true-negative (TN) results. The methodological quality of each study was assessed by Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS)11. The data were extracted and reviewed independently 
by two authors (LZH and GW).
Data analysis
Mantel-Haenszel odds ratios (ORs) and random-effects model were used to examine the effect size of each individual DNA methylation, and the results were presented in a forest plot. According to these results, only significantly differentially methyl-ated genes were selected for further testing. Pooled estimates on sensitivity, 
specificity, positive likelihood ratio 
(PLR), negative likelihood ratio (NLR) 
and diagnostic odds ratio (DOR) were employed to examine the diagnostic accuracy of methylated genes in LSCC. Pooled estimates of sensitivity and specificity were used to construct the hierarchical sum-mary receiver operating characteris-
tic (SROC) curves. The area under the 
curve (AUC) was used to measure the summary diagnostic value. The heterogeneity between studies was assessed by the test of inconsistency 
using I-squared statistic. I2 ≥ 50% was considered as substantial heteroge-neity. Publication bias was detected by 
the Deeks’ funnel plot asymmetry test12. A P value of less than 0.1 for the slope coefficient was considered as significant asymmetry, which indicated potential publication bias. All analysis was performed with Stata software version 11.0.
Results
Study characteristics and quality
A total of 551 potential relevant papers were identified from PubMed, 
EMBASE, Medline and Springer link (Figure 1). Among these papers, 278 
and 24 articles were excluded due to duplicated identification and irrele-
vance, respectively. Moreover, 4 papers in the language other than English or Chinese were excluded. Subse-
quently, 22 reviews and 25 non-case-control studies were excluded from 
the remaining 95 papers in the sec-ond round after detailed evaluation. 
In the final round, 26 articles without gene methylation frequency data, 3 
articles studying microRNA methyl-ation and 3 articles without available 
Figure 1: Flow diagram showing the literature search strategy and review process. 
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methylation frequency in LSCC were excluded. Finally, 27 case-control 
studies reporting methylation of 16 individual genes were selected for meta-analysis (Table 1). The quality of selected articles was evaluated using 
quality assessment for studies of 
diagnostic accuracy (QUADAS). How-
ever, 13 of the 16 articles were consid-ered as high quality with a score of 10, while the other 3 had a score of 9 (Table 1).
Genes differentially methylated 
between LSCC tumour tissue  
and normal controlSignificant differentially methylated 
genes were detected in 6 of the 16 
individual genes (Table 2). All 6 genes 
Table 1 Study characteristics. Twenty-seven studies from 16 publications were included. Studies 8–19 were reported in 
the same article
First author Year Country QUADAS 
score
Research 
genes 
LSCC Normal Methods TP FP FN TN
1 Yang13 2012 China 10 MYCT1 73 73 BSP base-
sequencing
59 13 14 60
2 Li14 2012 China 9 BRMS1 70 60 MSP 34 0 36 60
3 Hartmann15 2011 Poland 10 GNG7 98 8 BSP base-
sequencing
42 0 56 8
4 Yang16 2011 China 10 RASSF1A 50 15 MSP 31 0 19 15
5 Wang17 2011 China 10 CHD5 65 65 BSP base-
sequencing
39 9 26 56
6 Tawfik18 2010 Egypt 10 HMLH1 26 49 MSP 6 10 20 39
7 He19 2010 China 10 SPARC 41 9 MSP 23 1 18 8
8 Paluszczak20 2010 Poland 9 RARbeta 41 40 MSP 24 17 17 24
9 Paluszczak20 2010 Poland 9 RARbeta 41 40 MSP 24 19 17 21
10 Paluszczak20 2010 Poland 9 RASSF1A 41 40 MSP 13 9 28 32
11 Paluszczak20 2010 Poland 9 RASSF1A 41 40 MSP 13 9 28 32
12 Paluszczak20 2010 Poland 9 GSTP1 41 40 MSP 2 1 39 40
13 Paluszczak20 2010 Poland 9 GSTP1 41 40 MSP 2 2 39 39
14 Paluszczak20 2010 Poland 9 MGMT 41 40 MSP 22 15 19 26
15 Paluszczak20 2010 Poland 9 MGMT 41 40 MSP 22 15 19 25
16 Paluszczak20 2010 Poland 9 DAPK 41 40 MSP 31 32 10 9
17 Paluszczak20 2010 Poland 9 DAPK 41 40 MSP 31 32 10 9
18 Paluszczak20 2010 Poland 9 FHIT 34 40 MSP 9 8 25 26
19 Paluszczak20 2010 Poland 9 FHIT 34 40 MSP 9 7 25 27
20 He21 2010 China 10 CHFR 50 15 MSP 11 0 39 15
21 Brieger22 2010 Germany 9 HIC1 5 3 MSP 4 3 1 0
22 Tang23 2010 China   10 RUNX3 40 29 MSP 38 0 2 29
23 Xu24 2006 China 10 RASSF1A 48 48 MSP 34 11 14 37
24 Zhang25 2006 China 10 MGMT 46 51 MSP 16 0 30 51
25 Kong26 2005 China 10 DAPK 58 63 MSP 39 6 19 57
26 Yin27 2005 China 10 FHIT 41 41 MSP 10 0 31 41
27 Bai28 2000 China 10 p16 32 32 MSP 6 0 26 32
LSCC: laryngeal squamous cell carcinoma; MSP: methylation-specific PCR; TP: true positive; FP: false positive; FN: false negative; TN: true negative; QUADAS: 
quality assessment for studies of diagnostic accuracy (maximum score: 14).
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(RASSF1A, RUNX3, BRMS1, MYCT1, 
CHD5 and SPARC) showed a signifi-cantly higher methylation in the LSCC tumour tissue compared with that in 
the normal control. The 95% CI of their 
OR did not overlap the no effect value. 
Methylated RASSF1A was reported by multiples studies (Figure 2), and 
methylated RUNX3 demonstrated the largest effect size.
Diagnostic accuracy of DNA 
methylation in LSCC
The 6 genes were reported in 9 studies 
from 8 articles including 469 tumour tissue samples and 379 normal control tissue samples (Table 3). Methylation 
markers had a pooled sensitivity of 0.62 
(0.46–0.76), ranging from 0.32 to 0.95, 
and a pooled specificity of 0.91 (0.79–0.97), ranging from 0.77 to 1 (Figure 3). 
Heterogeneity between studies was observed in both sensitivity (Q-test = 
68.71, P < 0.01, I2 = 88.36) and speci-
ficity (Q-test = 31.56, P < 0.01, I2 = 
74.65) tests. Pooled PLR and pooled 
NLR were 7.2 (95% CI: 2.5–20.4) and 
0.42 (95% CI: 0.27–0.65), respectively. We also generated the Fagan nomo-
gram using PLR and NLR (Figure 4). 
With PLR and NLR of 7.2 and 0.42, the 
post-test probability increased to 64% from a given pre-test probability of 
20% when the index test was positive, 
and dropped to 9% when the index 
test was negative. DOR of the methyl-
ation markers was 17 [4, 69]. Figure 5 showed the summary receiver operat-
ing characteristic (SROC) curve, with 
the summary operating point as 0.62 of sensitivity and 0.91 of specificity. 
The area under the curve (AUC) was 
0.86. The summary likelihood matrix point was in the right lower quadrant 
(PLR <10 and NLR >0.1), indicating 
that the methylated DNA markers were not useful predicators for LSCC 
(Figure 6).
Publication biasThe selected studies were assessed based on the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS) items and scoring guideline12. 
Table 2 Differentially methylated genes in LSCC tumour tissues compared with 
the normal counterparts
Research 
genes
Studies Study ID No. in  
the figure
Overall OR [95% CI]
RASSF1A 4 Yang201116 ① 3.93 [1.236, 12.516]
Paluszczak201020 ②
Paluszczak201020 ③
Xu200624 ④
RUNX3 1 Tang201023 ⑧ 908.6 [42.01, 20000]
BRMS1 1 Li201214 ⑤ 114.37 [6.80, 1922.38]
MYCT1 1 Yang201213 ⑦ 19.45 [8.43, 44.88]
CHD5 1 Wang201117 ⑥ 9.33 [3.94, 22.08]
SPARC 1 He201019 ⑨ 10.2 [1.169, 89.388]
OR: odd ratio; 95% CI: 95% confidence intervals.
Table 3 The diagnostic accuracy of methylated DNA in LSCC. Pooled diagnostic 
accuracy
LSCC vs. normal control
No. of studies 9
Combined sensitivity [95% CI] 0.62 [0.46, 0.76]
Combined specificity [95% CI] 0.91 [0.79, 0.97]
PLR [95% CI] 7.2 [2.5, 20.4]
NLR [95% CI] 0.42 [0.27, 0.65]
DOR [95% CI] 17 [4, 69]
AUC [95% CI] 0.86 [0.82, 0.88]
OR: odds ratio; 95% CI: 95% confidence intervals; PLR: Positive likelihood ratio;  NLR: negative likelihood 
ratio; DOR: diagnostic odds ratio; AUC: area under the curve.
Figure 2: Forest plot of methylated RASSF1A gene in LSCC.
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According to QUADAS, publication score between 7 and 10 are qualified publication for meta-analysis. All 
selected studies had QUADAS of more 
than 8. Figure 7 showed the Deeks’ funnel plot asymmetry test12 based on the above 9 studies. The P-value was found to be 0.98, which was not statistically significant and indicated no potential publication bias.
DiscussionMethylated DNA is considered to be a 
surrogate biomarker as it could elabo-rate the indicative signals derived from 
cancer cells. It is present in the cancer-containing specimen as DNA methyla-tion is usually de novo and aberrant to the cancer cells. To the best of our 
knowledge, there is still no compre-
hensive evaluation on the diagnostic 
accuracy of methylation markers in the LSCC. Although there are numerous studies describing the potential use of 
methylated DNA as biomarkers in LSCC diagnosis, the diagnostic accuracy of 
these epigenetic markers in the clinical 
setting remains unclear. Hence, we performed a comprehensive review on 
the use of methylated DNA markers in detecting carcinoma arising from the laryngeal region.
In LSCC, most of the studies indicated that the detection rate of methylated 
DNA markers was significantly higher in comparison with the normal coun-
terparts. Of the 16 articles, 15 reported methylation of single methylated 
genes and 1 reported 5 methylated 
genes. Taken together, the data of 16 
methylated genes reported in 27 case-control studies were extracted. 
Methylation-specific PCR and bisulphite sequencing were used to detect the methylated gene in the 27 studies on 
2262 tissue samples (including 1221 
LSCC tissues and 1041 normal controls). 
Of the 16 genes, 37.5% (6/16) were found to be significantly different between the tumour tissues and the normal counterparts. Methylation-
specific PCR was used to detect 
RASSF1A, RUNX3, BRMS1, MYCT1 
and SPARC; bisulphite-sequencing was 
used to examine CHD5 methylation. Although real-time quantitative tech-nology (e.g. MethyLight) and high-throughput screening platform (e.g. methylation microarray) are available for the detection of methylation, these 
Figure 3: Forest plot of the pooled sensitivity, specificity, PLR, NLR and DOR. PLR: positive likelihood ratio; NLR: negative 
likelihood ratio; DOR: diagnostic odds ratio.
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are not used in LSCC. Methylated 
RUNX3 demonstrated the highest odd 
ratio among the 6 methylated genes. 
However, it was only reported in a 
single study with 40 cases. In com-
parison, methylated RASSF1A was 
reported in 4 studies on 159 cases. Fur-ther, only the qualitative examination 
method was used with no quantity data.
Theoretically, an ideal biomarker should be both sensitive and specific. 
It should also have a high positive and 
negative predictive value with 100% accuracy to differentiate the diseased group from the normal individuals29. 
In practice, the accuracy of cancer 
biomarkers varies depending on their intrinsic nature, generation mecha-nisms and extraction methods. To examine the property of methylation 
markers in LSCC, we first examined 
pooled sensitivity and specificity. In 
terms of sensitivity, methylation mark-ers had a high range, probably due to the intrinsic sensitivity difference between the different methylation 
markers selected by different groups. Cancers had a distinctive methyla-tion phenotype as they have differ-ent methylation patterns. Thus, the selection of candidate-methylated genes is important and is the deter-mining factor on the accuracy of the test. The present meta-analysis demon-
strated that methylated gene markers had a high pooled specificity (0.91). 
However, the pooled sensitivity is much 
lower (0.62) when we employ the meth-
ylation markers to examine the LSCC 
tissues. When we examined the AUC 
of SROC curve, methylation markers still showed an acceptable diagnostic 
performance (0.86). However, as indi-
cated in the pooled likelihood matrix, the current studies in the use methyla-
tion markers for LSCC diagnosis are neither exclusion nor confirmation. The heterogeneity observed across different studies is mainly caused by the use of different methylation 
markers as most studies employed the same detection method with 
QUADAS score over 9. Concerning the potential serological use of methyl-
ated DNA markers, all the studies reviewed in the present study exam-ined the laryngeal tissue alone. Attempt to use the cell-free methyl-
ated DNA as serological biomarkers in plasma or serum to differentiate 
Figure 4: Fagan nomogram. The red line indicates the probability change after positive index test, while the dash line indicates the probability change after 
negative index test. LR positive: positive likelihood ratio, LR negative: negative 
likelihood ratio.
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LSCC from normal individuals are 
not yet reported. Reports on the use of methylated DNA on other body fluids are also absent. Thus, we still have no information on the implication of methylated DNA as 
non-invasive biomarkers in LSCC management.Given the low sensitivity, methyl-
ation markers are not recommended for use in population screening due to 
the costs involved. However, the high 
specificity of methylation markers 
makes it a good tool for detecting the visually undetectable cancer cells in the biopsies samples obtained from 
the high-risk group as aberrant DNA methylation is an early event in cancer tumourigenesis. All reported 
methylated markers in LSCC had been reported in other human malignan-cies. Detection of the methylation 
markers in samples other than the laryngeal tissues (such as saliva, plasma and serum of the suspicious cases) could only reflect the potential 
risk of cancer and provide no informa-tion on the potential anatomical sites for further examination. Because only a few of the available methylation 
markers are evaluated in LSCC cases, the sensitivity and specificity 
of methylation markers could be improved when new candidate gene are evolved. To select suitable methyl-
ation markers for LSCC detection, it is important to identify the methylation patterns which are specific to LSCC and provide characteristic clinical infor-mation about the disease30. In conclu-sion, our results demonstrated that methylated DNA is good to differen-tiate cancerous laryngeal tissues from the normal counterparts based on 
its high specificity. However, at the present stages, the use of it in clinical setting is not recommended based on the limited data available. Further studies with the use of high-throughput technologies are warranted to explore novel and effective methylation 
markers for use in the diagnosis of LSCC.
Figure 5: Summary receiver operating characteristic (SORC) curve for 
individual studies on the diagnostic accuracy of methylated DNA markers. SENS: 
sensitivity; SPEC: specificity; AUC: area under the curve.
Figure 6: Likelihood ratio scatter plot matrix showing the association of 
methylated DNA markers with laryngeal carcinoma. The error bar shows the 95% 
confidence intervals. LRP: positive likelihood ratio, LRN: negative likelihood ratio, 
LUQ: left upper quadrant, RUQ: right upper quadrant, LLQ: left lower quadrant, 
RLQ: right lower quadrant.
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